New data provided by the HSE has revealed that since 2016 it has spent more than €1.2 billion on reimbursing biologic medicines, but just over €2.2 million on biosimilar medicines.
Annually, the HSE now reimburses biologics to the value of almost €450 million and €1 million on biosimilar medicines.
Data provided by the HSE on 26 March in response to a parliamentary question by Deputy John Brassil TD, Fianna Fail Junior Spokesperson on Primary Care and Community Health Services (see below) revealed the HSE spent the following amounts on biologic and biosimilar medicines over the last three years:
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
